摘要
目的:评价考来烯胺对Graves病的辅助疗效。方法:采用单盲、随机分组对照的设计方法,40例病人分成3组:①对照组用甲巯咪唑、普萘洛尔4周;②治疗1组用考来烯胺、甲巯咪唑、普萘洛尔4周;③治疗2组用考来烯胺、甲巯咪唑、普萘洛尔2周,后两周停用考来烯胺。结果:第2周末治疗1组较对照组总甲状腺素(TT4)和游离甲状腺素(FT4)下降明显,治疗2组与治疗1组相似,第4周末,TT4、FT4、总三碘甲状腺原氨酸(TT3)在治疗1组较对照组下降显著,治疗2组与对照组相近。最终治疗1组62%甲状腺功能正常,对照组只有8%。
Objective: To evaluate the adjunctive therapeutic effect of cholestyramine for Graves disease. Methods:A single blind, randomized control study was designed, 40 patients were assigned into three groups:①control group: methimazole and propranolol used for 4 weeks;②Cholestyramine treated group 1:methimazole, cholestyramine and propranolol for 4 weeks;③Cholestyramine treated group 2: cholestyramine for 2 weeks, followed by another 2 weeks of methimazole and propranolol. Results: At the end of the second week, TT 4 and FF 4 were significantly lower in group 1 than control group, while there was no difference between group 1 and group 2. At the end of week 4, TT 4,FT 4、TT 3 were significantly lower in both than in control group. By the end of the study, 62% patients in group 1, while only 8% patients in control group were in euthyroid state. Conclusion: Cholestryramine is an effective adjunctive agent for the treatment of Graves disease.
出处
《新医学》
1998年第5期242-243,共2页
Journal of New Medicine